title: Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
abstract: Eleven protease mutations have been associated with reduced susceptibility to darunavir (DRV). We examined the prevalence and covariates of these mutations in 2 populations. Thirty percent of 1175 Northern California patients and 24% of 2744 non-California patients in the Stanford HIV Drug Resistance Database had viruses with 1 or more mutations associated with resistance to DRV. In multivariate analyses, the number of DRV resistance-associated mutations depended on the number of previous protease inhibitors (PIs) administered and on amprenavir/fosamprenavir treatment. Most PI-treated patients should respond favorably to DRV-based salvage therapy.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
authors.forename: Yumi
authors.initials: Y
authors.lastname: Mitsuya
authors.forename: Tommy F
authors.initials: TF
authors.lastname: Liu
authors.forename: Soo-Yon
authors.initials: SY
authors.lastname: Rhee
authors.forename: W Jeffrey
authors.initials: WJ
authors.lastname: Fessel
authors.forename: Robert W
authors.initials: RW
authors.lastname: Shafer
mesh_terms: D002140:California / Q000453:epidemiology; D000069454:Darunavir; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics*; D015658:HIV Infections / Q000453:epidemiology / Q000235:genetics*; D016333:HIV Protease / Q000235:genetics; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D009154:Mutation; D015995:Prevalence; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D012189:Retrospective Studies; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D011480:Protease Inhibitors; D013449:Sulfonamides; D016333:HIV Protease; D000069454:Darunavir